Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R. Bartram, PhD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, Rita Beier, MD, Gunnar Cario, Franco Locatelli, MD, Giuseppe Basso, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter

Blood (2016) 128 (22): 4.

https://doi.org/10.1182/blood.V128.22.4.4

Published: 2016

Journal Articles

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Maria Grazia Valsecchi, PhD, Meenakshi Devidas, PhD, Ausiliatrice Lucenti, PhD, Martin Schrappe, MD, Giovanni Cazzaniga, PhD, Anja Moricke, MD, Claus R. Bartram, PhD, Georg Mann, MD, William L. Carroll, MD, Eric Larsen, MD, Naomi Winick, MD, Giuseppe Basso, MD, Valentino Conter, Martin Zimmermann, PhD, Stefan Sushu, Andrea Biondi, MD, Stephen Hunger, MD, Stefania Galimberti, PhD

Blood (2016) 128 (22): 759.

https://doi.org/10.1182/blood.V128.22.759.759

Published: 2016

Journal Articles

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

Blood (2016) 127 (17): 2101–2112.

https://doi.org/10.1182/blood-2015-09-670729

Published: 2016

Includes: Supplemental data

Journal Articles

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Blood (2014) 124 (21): 131.

https://doi.org/10.1182/blood.V124.21.131.131

Published: 2014

Journal Articles

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype

Blood (2013) 122 (19): 3298–3307.

https://doi.org/10.1182/blood-2013-03-491316

Published: 2013

Includes: Supplemental data

Journal Articles

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Tilmann Bochtler, MD, Ute Hegenbart, MD, Axel Benner, Dirk Hose, MD, Anja Seckinger, Kai Neben, MD, Sascha Dietrich, MD, Claus R Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Stefan O Schonland, MD

Blood (2011) 118 (21): 3946.

https://doi.org/10.1182/blood.V118.21.3946.3946

Published: 2011

Journal Articles

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Jan Zuna, MD, PhD, Mari Arens, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Anja Möricke, MD, Claus R Bartram, MD, Ruth Joas, Eva Fronkova, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Zimmermann, PhD, Jan Trka, MD, PhD, Jan Stary, M.D., Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, André Schrauder, MD

Blood (2011) 118 (21): 756.

https://doi.org/10.1182/blood.V118.21.756.756

Published: 2011

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Blood (2011) 118 (8): 2077–2084.

https://doi.org/10.1182/blood-2011-03-338707

Published: 2011

Includes: Supplemental data

Journal Articles

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, Axel Benner, Marion Moos, Anja Seckinger, Stephanie Pschowski-Zuck, Désirée Kirn, Kai Neben, Claus R. Bartram, Anthony D. Ho, Hartmut Goldschmidt, Dirk Hose, Anna Jauch, Stefan O. Schonland

Blood (2011) 117 (14): 3809–3815.

https://doi.org/10.1182/blood-2010-02-268987

Published: 2011

Journal Articles

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Petra Breithaupt, PhD, Barbara Meissner, MD, Martin Zimmermann, Anja Möricke, MD, André Schrauder, MD, Jochen Harbott, Wolf-Dieter Ludwig, MD, PhD, Rolf Köhler, PhD, Claus R Bartram, MD, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc

Blood (2010) 116 (21): 409.

https://doi.org/10.1182/blood.V116.21.409.409

Published: 2010

Journal Articles

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 1718.

https://doi.org/10.1182/blood.V116.21.1718.1718

Published: 2010

Journal Articles

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Blood (2010) 115 (16): 3206–3214.

https://doi.org/10.1182/blood-2009-10-248146

Published: 2010

Includes: Supplemental data

Journal Articles

Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood

Rashmi B. Prasad, Fay J. Hosking, Jayaram Vijayakrishnan, Elli Papaemmanuil, Rolf Koehler, Mel Greaves, Eamonn Sheridan, Andreas Gast, Sally E. Kinsey, Tracy Lightfoot, Eve Roman, Malcolm Taylor, Kathy Pritchard-Jones, Martin Stanulla, Martin Schrappe, Claus R. Bartram, Richard S. Houlston, Rajiv Kumar, Kari Hemminki

Blood (2010) 115 (9): 1765–1767.

https://doi.org/10.1182/blood-2009-09-241513

Published: 2010

Journal Articles

Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 .

Cornelia Eckert, Rolf Koehler, Thomas Flohr, Nikola Hagedorn, Anja Moericke, Martin Stanulla, Renate Kirschner-Schwabe, Gunnar Cario, Arend von Stackelberg, Claus R Bartram, Guenter Henze, Martin Schrappe, Andre Schrauder

Blood (2009) 114 (22): 2612.

https://doi.org/10.1182/blood.V114.22.2612.2612

Published: 2009

Journal Articles

Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.

Tilmann Bochtler, Ute Hegenbart, MD, Christiane Heiss, Axel Benner, Stephanie Pschowski-Zuck, Désirée Kirn, Kai Neben, Marion Moos, D. Hose, Claus R Bartram, MD, Anthony D. Ho, MD, PhD, Hartmut Goldschmidt, Anna Jauch, Stefan Schonland

Blood (2009) 114 (22): 2823.

https://doi.org/10.1182/blood.V114.22.2823.2823

Published: 2009

Journal Articles

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response

Blood (2009) 114 (5): 1053–1062.

https://doi.org/10.1182/blood-2008-10-186536

Published: 2009

Includes: Supplemental data

Journal Articles

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter, MD

Blood (2008) 112 (11): 7.

https://doi.org/10.1182/blood.V112.11.7.7

Published: 2008

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Andrea Biondi, André Schrauder, Maria Grazia Valsecchi, Claus R Bartram, Georg Mann, Giulio De Rossi, Anja Möricke, Rosanna Parasole, Jochen Harbott, Chiara Messina, C. Rizzari, Giuseppe Masera, Martin Schrappe

Blood (2008) 112 (11): 1511.

https://doi.org/10.1182/blood.V112.11.1511.1511

Published: 2008

Journal Articles

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

Thomas Burmeister, Stefan Schwartz, Claus R. Bartram, Nicola Gökbuget, Dieter Hoelzer, Eckhard Thiel

Blood (2008) 112 (3): 918–919.

https://doi.org/10.1182/blood-2008-04-149286

Published: 2008

NARROW

Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000)

Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood

Very Early/Early Relapses of ALL Show Unexpected Changes of Clonal Markers and High Heterogeneity in Initial and Relapse Treatment Response: ALL-BFM 2000 and ALL-REZ BFM 96/2002 .

Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.

High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only